Elevated Lp(a) clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).
Sylmar, California and other locations
Our lead scientists for Elevated Lp(a) research studies include Dianne S. Cheung, MD, MPH.
Last updated: